Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis
Open Access
- 5 October 2021
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 28 (5) , 3978-3986
Abstract
Immune checkpoint and MAP kinase pathway inhibitors can significantly improve long-term survival for patients with melanoma. There is limited real-world data of these regimens’ effectiveness. We retrospectively analyzed 402 patients with unresectable and metastatic melanoma between August 2013 and July 2020 treated with immune checkpoint inhibitors and MAP kinase pathway targeted therapy in Alberta, Canada. Overall survival (OS) was compared using Kaplan–Meier and Cox regression analyses. Subgroup survival outcomes were analyzed by first-line treatment regime and BRAF mutation status. Three treatment eras were defined based on drug access: prior to August 2013, August 2013 to November 2016, and November 2016 to July 2020. Across each era, there were improvements in median OS: 11.7 months, 15.9 months, and 33.6 months, respectively. Patients with BRAF mutant melanoma had improved median OS when they were treated with immunotherapy in the first line as opposed to targeted therapy (median OS not reached for immunotherapy versus 17.4 months with targeted treatment). Patients with BRAF wild-type melanomas had improved survival with ipilimumab and nivolumab versus those treated with a single-agent PD-1 inhibitor (median OS not reached and 21.2 months). Our real-world analysis confirms significant survival improvements with each subsequent introduction of novel therapies for advanced melanoma.Keywords
This publication has 20 references indexed in Scilit:
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsThe Lancet Oncology, 2016
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaJournal of Clinical Oncology, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaNew England Journal of Medicine, 2014
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010